Cargando…

Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks

Background. Levonorgestrel subdermal implants are preferred contraceptives with an expected failure rate of <1% over 5 years. We assessed the effect of efavirenz- or nevirapine-based antiretroviral therapy (ART) coadministration on levonorgestrel pharmacokinetics. Methods. This nonrandomized, par...

Descripción completa

Detalles Bibliográficos
Autores principales: Scarsi, Kimberly K., Darin, Kristin M., Nakalema, Shadia, Back, David J., Byakika-Kibwika, Pauline, Else, Laura J., Dilly Penchala, Sujan, Buzibye, Allan, Cohn, Susan E., Merry, Concepta, Lamorde, Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772838/
https://www.ncbi.nlm.nih.gov/pubmed/26646680
http://dx.doi.org/10.1093/cid/civ1001
_version_ 1782418635160027136
author Scarsi, Kimberly K.
Darin, Kristin M.
Nakalema, Shadia
Back, David J.
Byakika-Kibwika, Pauline
Else, Laura J.
Dilly Penchala, Sujan
Buzibye, Allan
Cohn, Susan E.
Merry, Concepta
Lamorde, Mohammed
author_facet Scarsi, Kimberly K.
Darin, Kristin M.
Nakalema, Shadia
Back, David J.
Byakika-Kibwika, Pauline
Else, Laura J.
Dilly Penchala, Sujan
Buzibye, Allan
Cohn, Susan E.
Merry, Concepta
Lamorde, Mohammed
author_sort Scarsi, Kimberly K.
collection PubMed
description Background. Levonorgestrel subdermal implants are preferred contraceptives with an expected failure rate of <1% over 5 years. We assessed the effect of efavirenz- or nevirapine-based antiretroviral therapy (ART) coadministration on levonorgestrel pharmacokinetics. Methods. This nonrandomized, parallel group, pharmacokinetic evaluation was conducted in three groups of human immunodeficiency virus–infected Ugandan women: ART-naive (n = 17), efavirenz-based ART (n = 20), and nevirapine-based ART (n = 20). Levonorgestrel implants were inserted at baseline in all women. Blood was collected at 1, 4, 12, 24, 36, and 48 weeks. The primary endpoint was week 24 levonorgestrel concentrations, compared between the ART-naive group and each ART group by geometric mean ratio (GMR) with 90% confidence interval (CI). Secondary endpoints included week 48 levonorgestrel concentrations and unintended pregnancies. Results. Week 24 geometric mean levonorgestrel concentrations were 528, 280, and 710 pg/mL in the ART-naive, efavirenz, and nevirapine groups, respectively (efavirenz: ART-naive GMR, 0.53; 90% CI, .50, .55 and nevirapine: ART-naive GMR, 1.35; 90% CI, 1.29, 1.43). Week 48 levonorgestrel concentrations were 580, 247, and 664 pg/mL in the ART-naive, efavirenz, and nevirapine groups, respectively (efavirenz: ART-naive GMR, 0.43; 90% CI, .42, .44 and nevirapine: ART-naive GMR, 1.14; 90% CI, 1.14, 1.16). Three pregnancies (3/20, 15%) occurred in the efavirenz group between weeks 36 and 48. No pregnancies occurred in the ART-naive or nevirapine groups. Conclusions. Within 1 year of combined use, levonorgestrel exposure was markedly reduced in participants who received efavirenz-based ART, accompanied by contraceptive failures. In contrast, nevirapine-based ART did not adversely affect levonorgestrel exposure or efficacy. Clinical Trials Registration. NCT01789879.
format Online
Article
Text
id pubmed-4772838
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-47728382016-03-01 Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks Scarsi, Kimberly K. Darin, Kristin M. Nakalema, Shadia Back, David J. Byakika-Kibwika, Pauline Else, Laura J. Dilly Penchala, Sujan Buzibye, Allan Cohn, Susan E. Merry, Concepta Lamorde, Mohammed Clin Infect Dis Articles and Commentaries Background. Levonorgestrel subdermal implants are preferred contraceptives with an expected failure rate of <1% over 5 years. We assessed the effect of efavirenz- or nevirapine-based antiretroviral therapy (ART) coadministration on levonorgestrel pharmacokinetics. Methods. This nonrandomized, parallel group, pharmacokinetic evaluation was conducted in three groups of human immunodeficiency virus–infected Ugandan women: ART-naive (n = 17), efavirenz-based ART (n = 20), and nevirapine-based ART (n = 20). Levonorgestrel implants were inserted at baseline in all women. Blood was collected at 1, 4, 12, 24, 36, and 48 weeks. The primary endpoint was week 24 levonorgestrel concentrations, compared between the ART-naive group and each ART group by geometric mean ratio (GMR) with 90% confidence interval (CI). Secondary endpoints included week 48 levonorgestrel concentrations and unintended pregnancies. Results. Week 24 geometric mean levonorgestrel concentrations were 528, 280, and 710 pg/mL in the ART-naive, efavirenz, and nevirapine groups, respectively (efavirenz: ART-naive GMR, 0.53; 90% CI, .50, .55 and nevirapine: ART-naive GMR, 1.35; 90% CI, 1.29, 1.43). Week 48 levonorgestrel concentrations were 580, 247, and 664 pg/mL in the ART-naive, efavirenz, and nevirapine groups, respectively (efavirenz: ART-naive GMR, 0.43; 90% CI, .42, .44 and nevirapine: ART-naive GMR, 1.14; 90% CI, 1.14, 1.16). Three pregnancies (3/20, 15%) occurred in the efavirenz group between weeks 36 and 48. No pregnancies occurred in the ART-naive or nevirapine groups. Conclusions. Within 1 year of combined use, levonorgestrel exposure was markedly reduced in participants who received efavirenz-based ART, accompanied by contraceptive failures. In contrast, nevirapine-based ART did not adversely affect levonorgestrel exposure or efficacy. Clinical Trials Registration. NCT01789879. Oxford University Press 2016-03-15 2015-12-08 /pmc/articles/PMC4772838/ /pubmed/26646680 http://dx.doi.org/10.1093/cid/civ1001 Text en © The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, contact journals.permissions@oup.com.
spellingShingle Articles and Commentaries
Scarsi, Kimberly K.
Darin, Kristin M.
Nakalema, Shadia
Back, David J.
Byakika-Kibwika, Pauline
Else, Laura J.
Dilly Penchala, Sujan
Buzibye, Allan
Cohn, Susan E.
Merry, Concepta
Lamorde, Mohammed
Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks
title Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks
title_full Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks
title_fullStr Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks
title_full_unstemmed Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks
title_short Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks
title_sort unintended pregnancies observed with combined use of the levonorgestrel contraceptive implant and efavirenz-based antiretroviral therapy: a three-arm pharmacokinetic evaluation over 48 weeks
topic Articles and Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772838/
https://www.ncbi.nlm.nih.gov/pubmed/26646680
http://dx.doi.org/10.1093/cid/civ1001
work_keys_str_mv AT scarsikimberlyk unintendedpregnanciesobservedwithcombineduseofthelevonorgestrelcontraceptiveimplantandefavirenzbasedantiretroviraltherapyathreearmpharmacokineticevaluationover48weeks
AT darinkristinm unintendedpregnanciesobservedwithcombineduseofthelevonorgestrelcontraceptiveimplantandefavirenzbasedantiretroviraltherapyathreearmpharmacokineticevaluationover48weeks
AT nakalemashadia unintendedpregnanciesobservedwithcombineduseofthelevonorgestrelcontraceptiveimplantandefavirenzbasedantiretroviraltherapyathreearmpharmacokineticevaluationover48weeks
AT backdavidj unintendedpregnanciesobservedwithcombineduseofthelevonorgestrelcontraceptiveimplantandefavirenzbasedantiretroviraltherapyathreearmpharmacokineticevaluationover48weeks
AT byakikakibwikapauline unintendedpregnanciesobservedwithcombineduseofthelevonorgestrelcontraceptiveimplantandefavirenzbasedantiretroviraltherapyathreearmpharmacokineticevaluationover48weeks
AT elselauraj unintendedpregnanciesobservedwithcombineduseofthelevonorgestrelcontraceptiveimplantandefavirenzbasedantiretroviraltherapyathreearmpharmacokineticevaluationover48weeks
AT dillypenchalasujan unintendedpregnanciesobservedwithcombineduseofthelevonorgestrelcontraceptiveimplantandefavirenzbasedantiretroviraltherapyathreearmpharmacokineticevaluationover48weeks
AT buzibyeallan unintendedpregnanciesobservedwithcombineduseofthelevonorgestrelcontraceptiveimplantandefavirenzbasedantiretroviraltherapyathreearmpharmacokineticevaluationover48weeks
AT cohnsusane unintendedpregnanciesobservedwithcombineduseofthelevonorgestrelcontraceptiveimplantandefavirenzbasedantiretroviraltherapyathreearmpharmacokineticevaluationover48weeks
AT merryconcepta unintendedpregnanciesobservedwithcombineduseofthelevonorgestrelcontraceptiveimplantandefavirenzbasedantiretroviraltherapyathreearmpharmacokineticevaluationover48weeks
AT lamordemohammed unintendedpregnanciesobservedwithcombineduseofthelevonorgestrelcontraceptiveimplantandefavirenzbasedantiretroviraltherapyathreearmpharmacokineticevaluationover48weeks